Terri Ridenour
Immunology and Microbiology · University of Michigan
Publications
24
Citations
164
Est. group size
—
Recurring co-author estimate
Active years
10
Publishing since 2017
Typically publishes in teams of ~10 · 0% small-team papers (≤3 authors) · across 14 venues
- Optimizing the key information section of informed consent documents in biomedical research: A multi-phased study using large language models
Journal of Clinical and Translational Science · 2026
- Obtaining a probability sample of a pregnancy cohort of births: a review of the problem and a practical solution
American Journal of Epidemiology · 2025
- Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis Over 18 Months in the USA
Clinical Drug Investigation · 2023
- Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
PharmacoEconomics - Open · 2022
- Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
Journal of Medical Economics · 2022
- Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
Figshare · 2022
- Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over two years of follow-up in real-world settings
Figshare · 2022
- Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings
Journal of the American Academy of Dermatology · 2021
- Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months
Dermatology and Therapy · 2021
- Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis
Pediatric Dermatology · 2021
- 26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients
Journal of the American Academy of Dermatology · 2021
- PBI17 Comparison of Switching Patterns Among Patients with Psoriasis Using Ixekizumab or Secukinumab in Real-World Settings
Value in Health · 2021
- 26291 Rapid skin improvement with ixekizumab treatment for pediatric patients with psoriasis: Results from IXORA-peds
Journal of the American Academy of Dermatology · 2021
- L’ixékizumab a démontré une efficacité élevée et durable ainsi qu’un profil de tolérance cohérent chez des patients atteints de psoriasis modéré à sévère : 5 ans de suivi dans l’étude UNCOVER 3
Annales de Dermatologie et de Vénéréologie · 2020
- Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis
Journal of the Dermatology Nurses’ Association · 2019
- Journal of the American Academy of Dermatology×6
- PubMed×3
- Value in Health×2
- Figshare×2
- Dermatology and Therapy×1
- Kelly A. Reynolds
Immunology and Microbiology · University of Michigan
- Jiaying Guo
Immunology and Microbiology · Indiana University
- James T. Elder
Immunology and Microbiology · University of Michigan
- Charles N. Ellis
Immunology and Microbiology · University of Michigan
- Allison C. Billi
Immunology and Microbiology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile